Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Abstract

Research in DLBCL pathogenesis has largely focused on the lymphoma cells that defined molecular subtypes. To elucidate the role of the lymphoma microenvironment (LME) in this process, we developed and deconvoluted transcriptomics signatures of LME cells and pathways from 3,026 DLBCLs from 13 datasets including our new cohort of 127 pts. Mutations were available for 562 pts of the datasets and for 22 pts from our cohort (WES with matched normal). Applying density-based clustering we identified 4 LME signatures, independent of reported transcriptional and genetic classifications based on lymphoma cells: LME-1 DLBCLs (n=726, 24% - GCB/ABC: 35%/36%) were characterized by an "immunosuppressive" ME enriched for Tregs, myeloid-derived suppressor cells, CD8PD1high, natural killer and macrophages type 2 and prevalence of genetic mechanisms of immune escape in malignant cells such as mutations in B2M (33%) and CD70 (10%). Malignant cells in LME-1 DLBCL presented high activity of NF-kB and JAK/STAT signaling pathways, likely due to high frequency of co-occurring MYD88L265and CD79B mutations (40%) and the presence of a cytokine rich milieu including high expression of IL10, IL6 and TNFS13B. Good outcome genetic groups BN2 and EZB constituted 46% of pts LME-2 DLBCLs (n=484, 16% - GCB/ABC: 55%/30%) were characterized by an "anti-tumor immunity" ME enriched for T cells, follicular TH and follicular dendritic cells (FDC). Lymphoma cells presented the highest number of BCL2 translocations and EZH2 mutations (40%, p=0.001 vs. other LME groups) and activation of cell motility and chemotaxis pathways that likely account for the advance stage at presentation (70% were stages III/IV p=0.02 vs. 40-50% in the other LME groups). Lymphoma cells expressed higher levels of CCL20, CCR6 and CXCR5. Good outcome genetic groups BN2 and EZB constituted 74% of pts. Notably, ABC LME-2 DLBCLs had better prognosis that any other ABC DLBCL (p<0.007 n=848) and similar to GCB DLBCLs LME-3 DLBCLs (n=847, 28% - GCB/ABC: 56%/25%) were characterized by a "mesenchymal" ME enriched for cancer-associated fibroblasts (CAFs), reticular DC, FDC and endothelial cells. Lymphoma cells showed higher mutations in BCR/Pi3K signaling intermediates SGK1 and GNA13 (20 and 13%) and activation of the TGFB signaling and matrix remodeling pathways. LME-3 DLBCLs expressed higher levels of MMP9, MMP2, TIMP1 and TIMP2. Good outcome genetic groups BN2 and EZB constituted 75% of pts, and were no patients harboring NOTCH1 mutations. LME-3 DLBCL also had the higher proportion of non-cellular LME component represented by the extracellular matrix (ECM). Patients with DLBCL with higher ECM proportion had better progression free survival (p=0.0004). We specifically tested the ECM effect in a murine DLBCL model by analyzing changes in ECM proteins associated with disease progression by serial proteomics. DLBCL progression was accompanied by increase in lymphoma cells in detriment of CAFs and ECM proteins. Among them, we identified the small proteoglycan decorin (DCN). Accordingly, parental administration of recombinant DCN to DLBCL mice (n=10 vs vehicle n=10) decreased tumor volume (p<0.001) and lymphoma cell proliferation while improving the LME immune infiltrate LME-4 DLBCLs (n=969, 32% - GCB/ABC: 46%/38%) were characterized by a "depleted" ME with increased proportion of lymphoma cells with mutations in MYD88, PIM1 and HLA-C (36, 38 and 13%), higher genomic instability and epigenetic heterogeneity (by DNA methylation). Good outcome genetic groups BN2 and EZB constituted 68% of pts. Lymphoma cells showed activation of Pi3K signaling and hypermethylation and low expression of the TGFB mediator SMAD1 (p<0.01 vs other LME groups). In agreement with our demonstration that pharmacologically reversible SMAD1 hypermethylation drives chemoresistance in DLBCL (Cancer Discovery 2013), patients with LME-4 DLBCL had less favorable outcomes in overall survival (HR=1.65 P<0.005 n=1,980) and response to immunochemotherapy (p<0.0001 n=810) than any other LME groups; likely reflecting the acquisition of ME-autonomous survival mechanisms by lymphoma cells. The bad outcome of LME-4 DLBCLs was not dependent on MYC/BCL2 or BCL6 double translocations, or the overall mutational load. In sum, ME signatures in DLBCL associate with clinical outcomes independently of existing molecular subtypes, contribute to explain DLBCL biology and provide potential novel therapies Disclosures Rutherford: Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Honoraria; Verastem: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Heron: Consultancy, Honoraria; Janssen Scientific Affairs: Consultancy, Honoraria; Juno Therapeutics Inc: Consultancy, Honoraria. Martin:Celgene: Consultancy; Teneobio: Consultancy; Sandoz: Consultancy; I-MAB: Consultancy; Karyopharm: Consultancy; Janssen: Consultancy. Leonard:Nordic N

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2019-128889

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 8

Metadata

Authors
Cerchietti, L., Inghirami, G., Kotlov, N., Svekolkin, V., Bagaev, A., Frenkel, F., Revuelta, M. V., Phillip, J. M., Cacciapuoti, M. T., Rutherford, S. C., Martin, P., & Leonard, J. P.
Affiliations
  • Weill Cornell Medicine (US)
  • BostonGene Corporation, Boston,
Venue
Blood
Published
2019-11-13
Volume
134
Issue
Supplement_1
Pages
656-656
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2989568741
Cited by
7
References
0
Citations by year
2025: 1 · 2023: 1 · 2021: 1 · 2020: 4
Type
conference abstract
Language
en
Open access
closed
Locations
Blood (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
Keywords
diffuse large B-cell lymphoma, lymphoma microenvironment, immune evasion, immunosuppressive microenvironment, antitumor immunity, MYD88 mutation, CD79B mutation, EZH2 mutation, BCL2 translocation, NF-κB signaling, JAK/STAT signaling, prognostic gene signature, molecular subtypes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. https://app.cochat.ai/papers/10.1182/blood-2019-128889
The paper
Cerchietti, L., Inghirami, G., Kotlov, N., Svekolkin, V., Bagaev, A., Frenkel, F., Revuelta, M. V., Phillip, J. M., Cacciapuoti, M. T., Rutherford, S. C., Martin, P., & Leonard, J. P. (2019). Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. Blood. https://doi.org/10.1182/blood-2019-128889

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.